Skip to main content
Top
Published in: Current Hypertension Reports 12/2015

01-12-2015 | Device-Based Approaches for Hypertension (M Schlaich, Section Editor)

Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension

Authors: Tatiana M. Ripp, Victor F. Mordovin, Stanislav E. Pekarskiy, Tamara R. Ryabova, Marina V. Zlobina, Andrei E. Baev, Yana Anfinogenova, Sergey V. Popov

Published in: Current Hypertension Reports | Issue 12/2015

Login to get access

Abstract

The aims of the study were to evaluate the effects of renal sympathetic denervation (RSD) on the heart and to identify the predictors of RSD efficacy in patients with resistant arterial hypertension. The study comprised 60 RSD patients (54.6 ± 9.5 years) who received full-dose antihypertensive therapy (4.1 drugs) including diuretics. Initially, 58.6 % of patients had abnormal left ventricular (LV) diastolic function. All patients received echocardiography before and 24 weeks after RSD. Renal sympathetic denervation was achieved through the endovascular radiofrequency ablation (RFA) of the renal arteries. Drug therapy continued for the entire period of observation. After RSD, all patients were retrospectively assigned to two groups: group 1 comprised patients (n = 22; 36.7 %) in whom the myocardial mass (MM) of the left ventricle decreased by more than 10 g after RSD; group 2 comprised patients (n = 38; 63.3 %) in whom LV MM increased or decreased by less than 10 g. Anthropometry, arterial blood pressure, heart rate, therapy, and LV end-diastolic dimensions (EDD) were comparable in these groups. After RSD, the values of office blood pressure significantly decreased and MM regressed by more than 10 g in 36.7 % of patients; LV diastolic function normalized in 31 % of patients, and diastolic dysfunction improved in 14 % of patients. The study found the associations between the initial LV wall dimensions and LV MM changes. Unlike LV EDD, arterial blood pressure, or heart rate, the initial values of LV wall thickness predicted LV MM regress. Trial registration: #NCT01499810 https://​clinicaltrials.​gov/​ct2/​show/​NCT01499810.
Literature
1.
go back to reference Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26. doi:10.1161/CIRCULATIONAHA.108.189141.CrossRefPubMed Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26. doi:10.​1161/​CIRCULATIONAHA.​108.​189141.CrossRefPubMed
2.
go back to reference Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. doi:10.1097/01.hjh.0000431740.32696.cc.CrossRefPubMed Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. doi:10.​1097/​01.​hjh.​0000431740.​32696.​cc.CrossRefPubMed
3.
go back to reference Urban D, Ewen S, Ukena C, Linz D, Böhm M, Mahfoud F. Treating resistant hypertension: role of renal denervation. Integr Blood Press Control. 2007;6:119–28. Urban D, Ewen S, Ukena C, Linz D, Böhm M, Mahfoud F. Treating resistant hypertension: role of renal denervation. Integr Blood Press Control. 2007;6:119–28.
6.
go back to reference Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34(4 Pt 2):724–8.CrossRefPubMed Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34(4 Pt 2):724–8.CrossRefPubMed
7.
go back to reference Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.CrossRefPubMed Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.CrossRefPubMed
8.
go back to reference Cuspidi C, Sala C, Negri F, Mancia G, Morganti A, Italian Society of Hypertension. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26(6):343–9. doi:10.1038/jhh.2011.104.CrossRefPubMed Cuspidi C, Sala C, Negri F, Mancia G, Morganti A, Italian Society of Hypertension. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26(6):343–9. doi:10.​1038/​jhh.​2011.​104.CrossRefPubMed
9.
go back to reference Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens. 2009;27(12):2458–64. doi:10.1097/HJH.0b013e328330b845.CrossRefPubMed Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens. 2009;27(12):2458–64. doi:10.​1097/​HJH.​0b013e328330b845​.CrossRefPubMed
11.
go back to reference Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. doi:10.1016/S0140-6736(09)60566-3.CrossRefPubMed Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. doi:10.​1016/​S0140-6736(09)60566-3.CrossRefPubMed
12.
go back to reference Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. doi:10.1016/S0140-6736(10)62039-9.CrossRef Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. doi:10.​1016/​S0140-6736(10)62039-9.CrossRef
15.
go back to reference Guo H, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. Int J Clin Exp Med. 2015;8(5):7270–8.PubMedCentralPubMed Guo H, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. Int J Clin Exp Med. 2015;8(5):7270–8.PubMedCentralPubMed
16.
go back to reference Tan LH, Li XG, Guo YZ, Tang XH, Yang K, Jiang WH. Effect of renal sympathetic denervation on left ventricular hypertrophy and inflammatory factors in spontaneously hypertensive rats. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013;42(5):550–5.PubMed Tan LH, Li XG, Guo YZ, Tang XH, Yang K, Jiang WH. Effect of renal sympathetic denervation on left ventricular hypertrophy and inflammatory factors in spontaneously hypertensive rats. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013;42(5):550–5.PubMed
17.
go back to reference Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–9. doi:10.1016/j.jacc.2011.11.034.CrossRefPubMed Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–9. doi:10.​1016/​j.​jacc.​2011.​11.​034.CrossRefPubMed
18.
go back to reference Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108.CrossRefPubMed Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108.CrossRefPubMed
19.
go back to reference Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–8.CrossRefPubMed Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–8.CrossRefPubMed
21.
go back to reference Linz D, Hohl M, Schütze J, Mahfoud F, Speer T, Linz B, et al. Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats: the role of renal sympathetic innervation. Am J Hypertens. 2015;28(2):256–65. doi:10.1093/ajh/hpu123.CrossRefPubMed Linz D, Hohl M, Schütze J, Mahfoud F, Speer T, Linz B, et al. Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats: the role of renal sympathetic innervation. Am J Hypertens. 2015;28(2):256–65. doi:10.​1093/​ajh/​hpu123.CrossRefPubMed
22.
go back to reference Dai Z, Yu S, Zhao Q, Meng Y, He H, Tang Y, et al. Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model. EuroIntervention. 2014;10(3):392–9. doi:10.4244/EIJV10I3A65.CrossRefPubMed Dai Z, Yu S, Zhao Q, Meng Y, He H, Tang Y, et al. Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model. EuroIntervention. 2014;10(3):392–9. doi:10.​4244/​EIJV10I3A65.CrossRefPubMed
23.
go back to reference Schirmer SH, Sayed MM, Reil JC, Ukena C, Linz D, Kindermann M, et al. Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol. 2014;63(18):1916–23. doi:10.1016/j.jacc.2013.10.073.CrossRefPubMed Schirmer SH, Sayed MM, Reil JC, Ukena C, Linz D, Kindermann M, et al. Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol. 2014;63(18):1916–23. doi:10.​1016/​j.​jacc.​2013.​10.​073.CrossRefPubMed
Metadata
Title
Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension
Authors
Tatiana M. Ripp
Victor F. Mordovin
Stanislav E. Pekarskiy
Tamara R. Ryabova
Marina V. Zlobina
Andrei E. Baev
Yana Anfinogenova
Sergey V. Popov
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 12/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-015-0603-8

Other articles of this Issue 12/2015

Current Hypertension Reports 12/2015 Go to the issue

Prevention of Hypertension: Public Health Challenges (P Muntner, Section Editor)

Interventions to Improve Medication Adherence in Hypertensive Patients: Systematic Review and Meta-analysis

Pathogenesis of Hypertension (W Elliott, Section Editor)

Dysregulated Blood Pressure: Can Regulating Emotions Help?

Hypertension and the Heart (SD Solomon and O Vardeny, Section Editors)

Sleep Disordered Breathing: Hypertension and Cardiac Structure and Function

Hypertension and the Brain (S Stocker, Section Editor)

Neurohumoral Integration of Cardiovascular Function by the Lamina Terminalis

Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

PPARγ Regulation in Hypertension and Metabolic Syndrome

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.